Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer

Oncogene

Volumn 23, Issue 13, 2004, Pages 2367-2378

  Punj, Vasu ^a   Bhattacharyya, Suchita ^a   Saint Dic, Djenann ^a   Vasu, Chenthamarakshan ^a   Cunningham, Elizabeth A ^a   Graves, Jewell ^a   Yamada, Tohru ^a   Constantinou, Andreas I ^a   Christov, Konstantin ^a   White, Bethany ^a   Li, Gang ^a   Majumdar, Dibyen ^a   Chakrabarty, Ananda M ^a   Das Gupta, Tapas K ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apoptosis; Breast cancer; Cupredoxin azurin

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; AZURIN; BACTERIAL TOXIN; CASPASE 7; CASPASE 9; COPPER PROTEIN; CYTOCHROME C; PROTEIN BAX; PROTEIN P53; CASPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL LEVEL; CYTOSOL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; BREAST TUMOR; DRUG EFFECT; METABOLISM;

ANIMALIA; BACTERIA (MICROORGANISMS); MINK CELL FOCUS-FORMING VIRUS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZURIN; BREAST NEOPLASMS; CASPASES; FEMALE; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842484823     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207376     Document Type: Article

References (66)

1. Alexandroff AB, Jackson AM, O'Donnell MA and James K. (1999). Lancet, 353, 1689-1694.
2. Altmann KH, Wartmann M and O'Reilly T. (2000). Biochim. Biophys. Acta, 1470, 78-91.
3. Asher G, Lotem J, Cohen B, Sachs L and Shaul Y. (2001). Proc. Natl. Acad. Sci. USA, 98, 1188-1193.
4. Bange J, Zwick E and Ullrich A. (2001). Nat. Med., 7, 548-552.
5. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jaggi R and Marti A. (2000). Cancer Res., 60, 4386-4390.
6. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM and Latchman DS. (1999). J. Biol. Chem., 274, 15237-15244.
7. Chakrabarty AM. (2003). J. Bacteriol., 185, 2683-2686.
8. Chandler JM, Cohen GM and MacFarlane M. (1998). J. Biol. Chem., 273, 10815-10818.
9. Chou TC, Zhang X, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR and Danishefsky SJ. (1998). Proc. Natl. Acad. Sci. USA, 95, 9642-9647.
10. Coley WB. (1911). Surg. Gynec. Obstet., 613, 174-190.
11. Cowan CM, Thai J, Krajewski S, Reed JC, Nicholson DW, Kaufmann SH and Roskams AJ. (2001). J. Neurosci., 21, 7099-7109.
12. Cuvillier O, Nava VE, Murthy SK, Edsall LC, Levade T, Milstien S and Spiegel S. (2001). Cell Death Differ., 8, 162-171.
13. Dang LH, Bettegowda C, Huso DL, Kinzler KW and Vogelstein B. (2001). Proc. Natl. Acad. Sci. USA, 98, 15155-15160.
14. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS and Reed JC. (1999). EMBO J., 18, 5242-5251.
15. Eilon GF, Gu J, Slater LM, Hara K and Jacobs JW. (2000). Cancer Chemother. Pharmacol., 45, 183-191.
16. Enari M, Sakahira H, Yokoyoma H, Okawa H, Iwamtsu A and Nagata S. (1998). Nature, 391, 43-50.
17. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M and Mollinedo F. (2000). Int. J. Cancer, 85, 674-682.
18. Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Das Gupta TK and Chakrabarty AM. (2003). Mol. Microbiol., 47, 549-559.
19. Gross A, Jockel J, Wei MC and Korsmeyer SJ. (1998). EMBO J., 17, 3878-3885.
20. Gross A, McDonnell J and Korsmeyer SJ. (1999). Genes Dev., 13, 1899-1911.
21. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS and Dong Z. (2003). Cancer Res., 63, 4396-4401.
22. Heerdt BG, Houston MA, Anthony GM and Augenlicht LH. (1999). Cancer Res., 59, 1584-1591.
23. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF and Fujii T. (1999). J. Biol. Chem., 274, 37461-37466.
24. Hu CC, Tang CH and Wang JJ. (2001). FEBS Lett., 503, 65-68.
25. Hu H, Ahn NS, Yang X, Lee YS and Kang KS. (2002). Int. J. Cancer, 102, 250-253.
26. Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, Golovkina TV, Evans S, Lee WF and Thomas-Tikhonenko A. (2001). J. Immunol., 166, 5878-5881.
27. Jain RK and Forbes NS. (2001). Proc. Natl. Acad. Sci. USA, 98, 14748-14750.
28. Janicke RU, Ng P, Sprengart ML and Porter AG. (1998). J. Biol. Chem., 273, 15540-15545.
29. Jemal A, Thomas A, Murray T and Thun M. (2002). CA Cancer J. Clin., 52, 23-47.
30. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA and Fang B. (2001). Clin. Cancer Res., 7, 1474-1480.
31. Lamoureux G, Turcotte R and Portelance Z. (1976). BCG in Cancer Immunotherapy. Grune and Stratton: New York.
32. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA and Bast Jr RC. (2001). Oncogene, 20, 8258-8269.
33. Lee ATC, Azimathol HCP and Tan AN. (2003). Cancer Cell Int., 43, 1-8.
34. Liang Y, Yan C and Schor NF. (2001). Oncogene, 20, 6570-6578.
35. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C and Denner L. (1998). Cancer Res., 58, 76-83.
36. Marchenko ND, Zaika A and Moll UM. (2000). J. Biol. Chem., 275, 16202-16212.
37. McGee MM, Hyland E, Campiani G, Ramunno A, Nacci V and Zisterer DM. (2002). FEBS Lett., 515, 66-70.
38. Meller R, Skradski SL, Simon RP and Henshall DC. (2002). Neurosci. Lett., 324, 33-36.
39. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM. (2003). Mol. Cell., 11, 577-590.
40. Mooney LM, Al-Sakkaf KA, Brown BL and Dobson PR. (2002). Br. J. Cancer, 7, 909-917.
41. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M. (1993). EMBO J., 12, 3679-3684.
42. Onuki R, Kawasaki H, Baba T and Taira K. (2003). Antisense Nucleic Acid Drug Dev., 13, 75-82.
43. Paglia P and Guzman CA. (1998). Cancer Immunol. Immunother., 46, 88-92.
44. Pawelek JM, Low KB and Bermudes D. (1997). Cancer Res., 57, 4537-4544.
45. Punj V and Chakrabarty AM. (2003). Cell Microbiol., 5, 225-231.
46. Punj V, Dasgupta TK and Chakrabarty AM. (2003). Biochem. Biophys. Res. Commun., 312, 109-114.
47. Raffo AJ, Kim AL and Fine RL. (2000). Oncogene, 19, 6216-6228.
48. Ralph P and Nakoinz I. (1975). Nature, 257, 393-394.
49. da Rocha AB, Lopes RM and Schwartsmann G. (2001). Curr. Opin. Pharmacol., 1, 364-389.
50. Runnebaum IB, Yee JK, Kieback DG, Sukumar S and Friedmann T. (1994). Anticancer Res., 14, 1137-1144.
51. Salomons GS, Brady HJ, Verwijs-Janssen M, Van Den Berg JD, Hart AA, Van Den Berg H, Behrendt H and Smets LA. (1997). Int. J. Cancer, 71, 959-965.
52. Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie Jr AW and Constantinou AI. (2000). Eur. J. Cancer, 36, 796-802.
53. Saunders PA, Cooper JA, Roodell MM, Schroeder DA, Borchert CJ, Isaacson AI, Schendel MJ, Godfrey KG, Cahill DR, Walz AM, Loegering RT, Gaylord H, Woyno IJ, Kaluyzhny AE, Kryzek RA, Mortari F, Tsang M and Roff CF. (2000). Anal. Biochem., 284, 114-124.
54. Schiffman K, Rinn K and Disis ML. (2002). Breast Cancer Res. Treat., 74, 17-23.
55. Sinha G. (2003). Nat. Med., 9, 1229.
56. Strasser A, O'Connor L and Dixit VM (2000). Annu. Rev. Biochem., 69, 217-245.
57. Sznol M, Lin SL, Bermudes D, Zheng LM and King I. (2000). J. Clin. Invest., 105, 1027-1030.
58. Talanian RV, Brady KD and Wong WW. (1997). J. Biol. Chem., 272, 9677-9682.
59. Tangri S, Ishioka GY, Glenn Y, Huang X, Sidney J, Southwood S, Fikes J and Sette A. (2001). J. Exp. Med., 194, 833-846.
60. Tong WG, Ding XZ, Witt RC and Adrian TE. (2002). Mol Cancer Ther., 1, 929-935.
61. Torchilin VP and Lukyanov AN. (2003). Drug Disc. Today, 8, 259-266.
62. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W and Kaufman SA. (1998). Genes Dev., 12, 806-819.
63. Wojciechowski J, Horky M, Gueorguieva M and Wesierska-Gadek J. (2003). Int. J. Cancer, 106, 486-495.
64. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, Majumdar D, Cunningham E, Das Gupta TK and Chakrabarty AM. (2002b). Proc. Natl. Acad. Sci. USA, 99, 14098-14103.
65. Yamada T, Goto M, Punj V, Zaborina O, Kimbara K, DasGupta TK and Chakrabarty AM. (2002a). Infect. Immun., 70, 7054-7062.
66. Zhivotovsky B, Samali A, Gahm A and Orrenius S. (1999). Cell Death Differ., 6, 644-651.